Researchers at UVA Health are embarking on a significant international partnership to enhance treatment options for pediatric cancers.The initiative, known as the C-Further international consortium, unites charities, biotech companies, and academic researchers in a concerted effort to develop new drugs specifically aimed at treating childhood cancers.
Source:
29news.comJohn Bushweller, a prominent researcher at UVA's Comprehensive Cancer Center, emphasized the importance of this collaboration.He noted that pharmaceutical companies often hesitate to invest in pediatric cancer treatments due to limited economic returns."We have to come up with clever ways to get around that so that we can develop novel new therapies specifically for pediatric cancers," Bushweller stated.
Source:
29news.comThe focus of Bushweller's research is Ewing sarcoma, a challenging form of pediatric bone cancer.Current treatment protocols, which include surgery, radiation, and intensive chemotherapy, can be harsh, particularly for young patients."A significant fraction of them survive from that treatment, but those who relapse or have metastatic disease do not do well," he explained.
Source:
29news.comThe C-Further consortium aims to develop more targeted therapies that could potentially improve outcomes for patients, particularly those facing relapses.Bushweller mentioned that the scientific expertise from universities can drive drug development, but the capabilities of biotech companies significantly enhance the likelihood of bringing effective treatments to clinical settings.
Source:
29news.comUVA Health is recognized globally for its groundbreaking medical research, which translates scientific discoveries into practical health solutions.The institution's strong funding from the National Institutes of Health and other partners supports its ongoing commitment to tackling complex medical challenges and innovating in the field of pediatric medicine.
Source:
uvahealth.comThe pediatric cancer initiative aligns with the broader mission of UVA Health's new Paul and Diane Manning Institute of Biotechnology, set to open in 2027.This facility will serve as a comprehensive hub for drug discovery and development, integrating all stages of the process from basic science to clinical trials.
Source:
uvahealth.comIn this evolving landscape of medical research, collaborations like the one between UVA Health and the C-Further consortium are crucial.They not only bring together diverse expertise but also aim to fill critical gaps in pediatric oncology where investment has been historically low.As part of this effort, researchers are hopeful that novel therapies could soon be translated from the laboratory into effective treatments for children battling cancer.
Sources:
29news.comuvahealth.comThrough initiatives like these, UVA Health continues to demonstrate its leadership in medical innovation, particularly in areas that require urgent attention and investment, such as pediatric cancer care.
